{"product_id":"gh-bcg-matrix","title":"(GH) Guardant Health, Inc. BCG Matrix Research","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-List-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSee the Bigger Picture\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThis Guardant Health, Inc. BCG Matrix is a company-specific tool used to assess its products or business units across Stars, Cash Cows, Question Marks, and Dogs for strategy, portfolio review, and capital allocation. The page already shows a real preview\/sample of the actual analysis, so you can see the format and content before buying. Purchase the full version to get the complete ready-to-use report instantly.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eStars\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGuardant360 CDx, FDA approved liquid biopsy\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGuardant360 CDx is Guardant Health, Inc.'s flagship FDA-approved liquid biopsy and companion diagnostic for advanced solid tumors, covering 74 genes. Guardant Health reported about $767 million in 2024 revenue, showing strong demand as liquid biopsy adoption keeps rising in oncology. Its broad clinical utility and high use in therapy selection support a Star position in the BCG Matrix.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGuardant360 LDT, advanced cancer profiling\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGuardant360 LDT is a Star in Guardant Health, Inc.'s BCG Matrix because it powers broad genomic profiling in advanced cancer care and remains one of the company's most established clinical tests. Repeat testing demand supports recurring use, while precision oncology adoption keeps the addressable market expanding. In Guardant Health, Inc.'s 2025 results, clinical test volume continued to scale, reinforcing this test's central role.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGuardant Reveal, MRD recurrence monitoring\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGuardant Reveal is a Star in Guardant Health, Inc.'s BCG mix: MRD and recurrence monitoring sits in a fast-growing oncology niche, with liquid biopsy adoption rising as early-stage care gets more data-driven and test-heavy. Guardant Health reported 2024 revenue of $697.9 million and $60.9 million in Q1 2025 revenue, showing growing scale for this platform. If adoption keeps accelerating, Reveal can expand well beyond its current footprint.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eGuardantINFORM, clinical genomic data platform\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eGuardantINFORM turns Guardant Health, Inc.'s large advanced-cancer liquid biopsy dataset into paid real-world evidence and analytics, so it is a clear Star in the BCG Matrix. Biopharma and research clients keep paying for faster trial design, biomarker insights, and post-market evidence, which supports a scalable, high-margin platform with strong data moats.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eData assets create stickiness.\u003c\/li\u003e\n\u003cli\u003eReal-world evidence demand is rising.\u003c\/li\u003e\n\u003cli\u003ePlatform scales without heavy lab cost.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eBiopharma companion diagnostics services, clinical development support\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eGuardant Health’s companion diagnostics and clinical development support is a Star in the BCG Matrix because it helps pharma partners move drugs through biomarker strategy, trial design, and regulatory approval.\u003c\/p\u003e\n\u003cp\u003eDemand stays tied to new launches and label expansions, especially as oncology outsourcing grows and more drug makers use outside diagnostic partners instead of building in-house teams.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSupports CDx development\u003c\/li\u003e\n\u003cli\u003eHelps drug approvals\u003c\/li\u003e\n\u003cli\u003eScales with label expansion\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGuardant Health’s Star Products Keep Driving Growth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eGuardant Health, Inc.'s Stars are its high-growth oncology tests and data tools, led by Guardant360 CDx, Guardant360 LDT, and Guardant Reveal. In 2025, clinical test volume kept scaling, and Q1 2025 revenue was $60.9 million for Reveal-backed growth. GuardantINFORM and companion diagnostics also benefit from rising biopharma demand.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eStar\u003c\/th\u003e\n\u003cth\u003eWhy it fits\u003c\/th\u003e\n\u003cth\u003eLatest data\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eGuardant360 CDx\u003c\/td\u003e\n\u003ctd\u003eFDA-approved CDx\u003c\/td\u003e\n\u003ctd\u003e74 genes\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGuardant Reveal\u003c\/td\u003e\n\u003ctd\u003eMRD growth\u003c\/td\u003e\n\u003ctd\u003e$60.9M Q1 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGuardantINFORM\u003c\/td\u003e\n\u003ctd\u003eData moat\u003c\/td\u003e\n\u003ctd\u003ePaid analytics\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"product-includes\"\u003e\n\u003cdiv class=\"product-includes__container\"\u003e\n\u003ch2 id=\"product-includes-title\" class=\"product-includes__title\"\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-includes__grid\"\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Detailed Word Document icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eGuardant Health's BCG Matrix maps its liquid biopsy lines into growth-and-share quadrants, guiding invest, hold, or divest choices.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Customizable Excel Spreadsheet icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eEditable Excel File\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eOne-page Guardant Health BCG Matrix that spotlights quadrant gaps and simplifies strategic decisions\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Reference-Icon.svg\" alt=\"References icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eReference Sources\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eProvides a clear source trail for Guardant Health assumptions, boosting credibility and helping decision-makers verify the model fast.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eCash Cows\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRoutine Guardant360 clinical volumes, advanced oncology base\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGuardant360’s routine advanced oncology volumes are Guardant Health, Inc.’s most repeatable cash engine, because orders are tied to standard treatment choices, not one-off screening demand. This core is steadier and more mature than early-stage products, so it supports recurring clinical revenue and cash generation. In BCG terms, it fits a Cash Cow: high share in an established testing market, with durable repeat use.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eReimbursement supported U.S. testing base, established payor coverage\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGuardant Health's U.S. testing base is a cash-cow style asset: Medicare and broad commercial coverage for core liquid biopsy tests lowers adoption friction and cuts the need for heavy promotion. In FY2024, revenue reached $737.7 million, showing the scale a covered testing base can support. Once reimbursement is set, revenue is steadier and each added test is cheaper to win.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical trial sample testing, recurring biopharma demand\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eClinical trial sample testing is a cash cow for Guardant Health, Inc. because biopharma sponsors need repeat testing for enrollment and biomarker checks across active programs. The work is tied to R\u0026amp;D pipelines, so demand stays recurring and usually swings less than launch-driven sales. That makes it a steadier revenue stream for the Guardant 360 and tissue-testing platform.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eKit fulfillment and assay support, operational services\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eKit fulfillment and assay support are classic cash cows for Guardant Health, Inc.: they tie directly to the core testing franchise, need limited market expansion, and can run efficiently at scale. These services help smooth cash flow because demand follows test volume, not heavy new sales investment.\u003c\/p\u003e\n\u003cp\u003eThat makes them margin-supportive and operationally reliable, even as Guardant Health keeps pushing higher-growth products. \u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eStable revenue tied to test volume\u003c\/li\u003e\n\u003cli\u003eLow incremental expansion needs\u003c\/li\u003e\n\u003cli\u003eSupports core testing margins\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eRegulatory support services, companion diagnostic maintenance\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eGuardant Health, Inc.'s regulatory support services and companion diagnostic maintenance are cash cows because they keep 2 FDA-approved companion diagnostics compliant, labeled, and usable in existing treatment programs. This work is slower-growth than new assay launches, but it protects recurring revenue around the core platform and helps keep approved tests on market for 2025\/2026 use.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2 approved companion diagnostics to maintain\u003c\/li\u003e\n\u003cli\u003eFocus on lifecycle and label support\u003c\/li\u003e\n\u003cli\u003eSteady revenue, not fast growth\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGuardant Health’s Cash Cows Drive Stable Revenue\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eGuardant Health, Inc.’s Cash Cows are its mature clinical testing and companion diagnostic services, led by Guardant360, Medicare-backed U.S. testing, and biopharma trial support. These units have repeat demand, low extra sales effort, and help stabilize cash flow; FY2024 revenue was $737.7 million, and the company maintained 2 FDA-approved companion diagnostics.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eCash cow\u003c\/th\u003e\n\u003cth\u003eSignal\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eGuardant360\u003c\/td\u003e\n\u003ctd\u003eRepeat advanced oncology use\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCompanion diagnostics\u003c\/td\u003e\n\u003ctd\u003e2 FDA-approved assets\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eWhat You See Is What You Get\u003c\/span\u003e\u003cbr\u003eGuardant Health, Inc. Reference Sources\u003c\/h2\u003e\n\u003cp\u003eThis Guardant Health, Inc. BCG Matrix preview is the exact file you’ll receive after purchase. What you see here is the full, ready-to-use document—no watermarks, no demo pages, and no hidden changes. Download it instantly after checkout and use it for analysis, reporting, or presentation with confidence.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eDogs\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGuardant-19, COVID 19 detection\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGuardant-19 was a pandemic-era COVID-19 test, not part of Guardant Health, Inc.'s oncology core. As coronavirus testing demand normalized, this product lost scale and strategic fit, so it sits in the low-growth, low-priority \"Dogs\" quadrant. In 2025, Guardant Health's business remained centered on oncology liquid biopsy and MRD, not COVID testing.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGuardantOMNI, broad panel liquid biopsy\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGuardantOMNI is a smaller, narrower liquid-biopsy panel than Guardant Health’s flagship tests, which drove 2024 revenue of $663.9M. In a crowded profiling market, it is not the main growth engine, so its share and upside look limited. That fits a \"dog\" in the BCG Matrix: low relative share, weak strategic priority.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTissue genotyping line, legacy workflow\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGuardant Health, Inc.'s tissue genotyping line is a mature legacy workflow, not a growth engine. The market is crowded with entrenched rivals like Thermo Fisher Scientific and Foundation Medicine, so growth is slower than the newer blood-based liquid biopsy products. In a BCG Matrix, this fits a Dog: low strategic priority and limited upside.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eSmall volume custom assay projects, one off work\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSmall volume custom assay projects are a Dogs fit for Guardant Health, Inc. because they stay tied to one-off client asks, so they use lab time and scientific staff without building repeatable scale. Guardant Health, Inc. reported 2024 revenue of $677.9 million, and custom work like this can dilute margin if it does not convert into recurring volume.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHigh effort, low repeatability\u003c\/li\u003e\n\u003cli\u003eClient-specific, not scalable\u003c\/li\u003e\n\u003cli\u003eWeak long-term growth profile\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eNon core legacy testing, limited expansion potential\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eGuardant Health, Inc.'s non-core legacy tests look like dog assets: they support the business, but they do not have a clear path to scale against the core liquid biopsy franchise. In 2025, Guardant Health reported $739.0 million in revenue, with growth still centered on Guardant360 and Shield, not older assay lines. That makes these legacy tests more of a maintenance item than a value driver.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSupport role, weak growth\u003c\/li\u003e\n\u003cli\u003eNot core to liquid biopsy\u003c\/li\u003e\n\u003cli\u003eRarely moves valuation\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGuardant Health’s Dogs: Legacy Assets With Little Growth Upside\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eGuardant Health, Inc.'s Dogs are non-core, low-share assets like Guardant-19, legacy tissue genotyping, and small custom assays. They do not drive 2025 growth, which came from Guardant360 and Shield, and they add more cost than scale.\u003c\/p\u003e\n\u003cp\u003eWith 2025 revenue at $739.0 million, these lines sit outside the main liquid biopsy engine. In BCG terms, they are maintenance assets with weak upside.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eDog asset\u003c\/th\u003e\n\u003cth\u003eWhy it fits\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eGuardant-19\u003c\/td\u003e\n\u003ctd\u003eCOVID demand faded\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTissue genotyping\u003c\/td\u003e\n\u003ctd\u003eLegacy, crowded market\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCustom assays\u003c\/td\u003e\n\u003ctd\u003eLow scale, low repeat use\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eQuestion Marks\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLUNAR 2, colorectal cancer screening\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eLUNAR 2 sits in a huge opportunity: the U.S. colorectal cancer screening pool tops 50 million adults aged 45-75, and the American Cancer Society projected about 154,270 new cases and 52,900 deaths in 2025. But fit is still a Question Mark because colonoscopy and FIT are entrenched, so Guardant Health, Inc. must spend hard on proof, reimbursement, and sales to win share. The upside is real, but adoption is still early and capital needs stay high.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGuardantConnect, clinical trial matching software\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGuardantConnect links actionable alterations to matched trials, so it fits a real biopharma pain point. Clinical trial matching is still fragmented, and Guardant Health, Inc. has shown the platform can sit inside a broader liquid biopsy workflow, but its commercial footprint remains small. That makes it a question mark: attractive need, unclear scale.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBlood based early detection, asymptomatic market\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBlood based early detection for asymptomatic patients is a high-upside Question Mark for Guardant Health, Inc. because the addressable cancer-detection market is still forming while company share is not locked in. The American Cancer Society projected about 2.0 million new U.S. cancer cases in 2026, and even a small share can scale fast, but adoption, reimbursement, and clinical proof still drive high risk. Guardant Health, Inc. is investing ahead of demand, so this segment can become a winner or stay a cash drain.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eCRC screening expansion, future launch pathway\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eCRC screening is a huge market: about 50 million U.S. adults are eligible for screening each year, and Shield was only FDA-approved in July 2024 for average-risk adults 45+. Guardant Health must turn that reach into real volume fast; until repeat adoption and reimbursement scale show up, it stays a question mark in the BCG matrix.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMass market, still early share\u003c\/li\u003e\n\u003cli\u003eFDA approval came in 2024\u003c\/li\u003e\n\u003cli\u003eScale and coverage are the key tests\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eMulti indication screening expansion, pipeline stage\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eGuardant Health, Inc.'s screening pipeline is still a question mark: Shield is approved for 1 screening indication, while expansion into 2+ uses could open a much larger addressable market. But each new test needs capital, clinical proof, and payer coverage, so share can stay small for years.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e1 approved indication today\u003c\/li\u003e\n\u003cli\u003e2+ uses could lift TAM\u003c\/li\u003e\n\u003cli\u003ePayer support drives adoption\u003c\/li\u003e\n\u003cli\u003eEvidence comes before share\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGuardant’s Shield Has a Huge Market, but Adoption Is Still Early\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eGuardant Health, Inc.'s Question Marks need proof and scale: Shield targets a U.S. CRC screening pool of 50M+ adults, but FDA approval only came in July 2024, so share is still early. Blood-based early detection also faces payer and evidence risk, even as 2026 U.S. cancer cases are projected at about 2.0M.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eItem\u003c\/th\u003e\n\u003cth\u003eLatest data\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCRC screening pool\u003c\/td\u003e\n\u003ctd\u003e50M+ adults\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eShield approval\u003c\/td\u003e\n\u003ctd\u003eJuly 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eU.S. cancer cases, 2026\u003c\/td\u003e\n\u003ctd\u003e~2.0M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"DCF Analyst","offers":[{"title":"Default Title","offer_id":57234410078473,"sku":"gh-bcg-matrix","price":5.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0942\/8045\/0313\/files\/gh-bcg-matrix.webp?v=1785719837","url":"https:\/\/dcfanalyst.com\/products\/gh-bcg-matrix","provider":"DCF Analyst","version":"1.0","type":"link"}